<DOC>
	<DOC>NCT00241098</DOC>
	<brief_summary>This is a study to evaluate the response of patients with hypertension and early stage heart failure to valsartan.</brief_summary>
	<brief_title>The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male or female 2585 years of age, inclusive Past diagnosis of hypertension for a min 1 year Patients with an established treatment regimen for hypertension with one or more agents for a minimum period of 2 months BP is considered adequately controlled with DBP &lt; 90mmHg Elevated BNP levels both in bedside test (62pg/ml) and after validation of a separate blood sample (40pg/ml) in the central laboratory LV ejection fraction ³ 45% LVH defined as myocardial mass ³ 116 g /m2 in males and 104 g/m2 in females At least one of the following parameters of diastolic dysfunction E/A &lt; 1 for the patients who are younger than 55 years or &lt; 0.8 for the patients whose age is ³ 55 years (full year), or DT &gt; 220 ms, or IVRT &gt; 90 ms • Present use of ACE inhibitor Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>HYPERTENSION</keyword>
	<keyword>HEART FAILURE</keyword>
	<keyword>PEPTIDE</keyword>
	<keyword>valsartan</keyword>
</DOC>